skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer

Review

(3086) Views  (842) Full article downloads

Authors: Serena Ricciardi, Silverio Tomao, Filippo de Marinis

Published Date September 2009 Volume 2009:5 Pages 781 - 787
DOI: http://dx.doi.org/10.2147/TCRM.S3195

Serena Ricciardi1, Silverio Tomao2, Filippo de Marinis1

1Thoracic-Oncology Unit 1st, Lung Diseases Department, San Camillo-Forlanini High Specialization Hospitals, Rome, Italy; 2Sperimental Medicine Department, Rome, Italy

Abstract: Pemetrexed is a new cytotoxic agent that is a standard of care for the second-line treatment of non-small cell lung cancer (NSCLC) and in combination with cisplatin in treatment of malignat pleural mesothelioma. It has been studied in numerous phase II and III trials in combination with different drugs or as single agent. Recently, pemetrexed has been approved in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic NSCLC other than squamous cell histology. The toxicity is acceptable and similar to that of other NSCLC regimens. The postinduction maintenance therapy with pemetrexed is being evaluated in a phase III, double-blind, placebo-controlled study.

Keywords: pemetrexed, non-small cell lung cancer, non-squamous carcinoma, first-line setting








Readers of this article also read:

Comparison of linear–stochastic and nonlinear–deterministic algorithms in the analysis of 15-minute clinical ECGs to predict risk of arrhythmic death
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium
Five-year alendronate treatment outcome in older postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fractures
Safety and efficacy of telbivudine for the treatment of chronic hepatitis B
The role of urate and xanthine oxidase in vascular oxidative stress: future directions
Artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea
Fesoterodine for the treatment of urinary incontinence and overactive bladder
Exercise-induced bronchoconstriction: The effects of montelukast, a leukotriene receptor antagonist